EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk

Share this post

The EMA’s safety committee advises physicians not to prescribe the 10-mg twice-daily dose of tofacitinib to patients who are at high risk for pulmonary embolism, pending results of an ongoing safety review.
News Alerts

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply